In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …

Background Interferon-containing regimens for the treatment of hepatitis C virus (HCV)
infection are associated with increased toxic effects in patients who also have cirrhosis. We …

Background The treatment of hepatitis C virus (HCV) has evolved dramatically after the
introduction of direct acting anti‐virals. NS 5A protein plays an important role in HCV …

Background & Aims The safety profiles of boceprevir and telaprevir in the treatment of
chronic hepatitis C, administered in academic and community centres across the United …

Due to the progressive aging of the hepatitis C virus (HCV) population which have acquired
the infection during its maximum spread after the Second World War, the management of the …

Patients who are infected with hepatitis C virus (HCV) and also have advanced fibrosis or
cirrhosis have been recognized as “difficult-to-treat” patients during an era when …

Background & Aims There is little information regarding the extent to which difficult to cure
patients with advanced liver fibrosis, due to hepatitis C virus genotype-1 (HCV-1) can …

European governments employ sophisticated health technology assessment and regulatory
procedures to identify which pharmaceuticals to fund publicly. However, there are persisting …

Hepatitis C Virus (HCV) infects 200 million individuals worldwide. Although several FDA
approved drugs targeting the HCV serine protease and polymerase have shown promising …

Many countries employ “alternative access schemes”(eg compassionate use, early access
programs, off-label use) that seek to provide patients with access to drugs not included on a …